Capsida Biotherapeutics Announces Publication in Nature Neuroscience From...
THOUSAND OAKS, Calif., December 9, 2021 — Capsida Biotherapeutics, Inc., an industry-leading gene therapy platform company creating a new class of targeted, non-invasive gene therapies for patients...
View ArticlePharmaVoice profiles Capsida CEO Peter Anastasiou
Capsida Biotherapeutics CEO Peter Anastasiou aims to bring AAV therapy to reality Anastasiou’s key to leadership stands at the intersection of what’s right for patients and business. As the CEO of...
View ArticleClik here to view.
Capsida Biotherapeutics Announces Appointment of Rayne Waller to Chief...
Company creates chief operating officer role and appoints veteran manufacturing and supply-chain executive Rayne Waller to help Capsida capitalize on its platform gene therapy technology, bringing...
View ArticleCapsida Co-Founders Named to Endpoints’ Top 20 Scientists Under 40
Dr. Nick Goeden and Dr. Nick Flytzanis – “the Nicks,” as many of their colleagues call them – have a lot in common. They’re both co-founders and leaders at Capsida Biotherapeutics. They’re both 35...
View ArticleCapsida Biotherapeutics Presents New Data Validating Potential of Its...
Preclinical results demonstrate proof-of-concept of early generation AAV-engineered capsid in MPSII pilot program Data from capsid engineering platform show greater than 100-fold improvement over AAV9...
View ArticleCapsida Biotherapeutics Presents Data Demonstrating Unique Industry-Leading...
Platform utilizes combinatorial engineering and automation to screen in high-throughput, generating capsids greatly improved over AAV9 in CNS efficiency and specificity Process development and...
View ArticleClik here to view.
Capsida Biotherapeutics Announces Strategic Collaboration with Prevail, a...
THOUSAND OAKS, Calif. January 4, 2023 – Capsida Biotherapeutics Inc. (“Capsida”) today announced a multi-year strategic collaboration with Prevail Therapeutics (“Prevail”), a wholly owned subsidiary...
View ArticleCapsida Biotherapeutics Announces Appointment of Julie Hakim as Chief...
Hakim brings more than 25 years’ experience leading finance and exponential growth at both large and small companies THOUSAND OAKS, Calif., January 18, 2023 — Capsida Biotherapeutics Inc. (“Capsida”)...
View ArticleAbbVie and Capsida Biotherapeutics Expand Strategic Collaboration to Develop...
Partnership Combines AbbVie’s extensive capabilities with Capsida’s novel adeno-associated virus (AAV) engineering platform Builds upon the neurodegenerative disease partnership announced in 2021 NORTH...
View ArticleCapsida Biotherapeutics Appoints Susan Catalano, Ph.D. as Chief Scientific...
Industry veteran added to complement co-founders Nicholas Flytzanis, Ph.D. and Nick Goeden, Ph.D., to build on Company’s excellence in next-generation gene therapy science and bolster efforts to...
View ArticleCapsida Biotherapeutics to Present New Data Showing Increased Capsid...
Preliminary data show next-generation engineered capsids in non-human primates delivered systemically resulted in widespread transduction in up to 68% of neurons across multiple brain regions Data to...
View ArticleCapsida Biotherapeutics to Present New Preclinical Data on Potential of...
Preclinical data show IV administration of a next-generation gene therapy produced dose-dependent replacement of syntaxin-binding protein 1 (STXBP1) throughout the brain, with efficacy predictive of...
View ArticleCapsida Biotherapeutics Announces Publication in Nature Nanotechnology...
Foundational research by Capsida and Caltech demonstrates ability to engineer AAVs with improved efficacy over AAV9 to transduce brain in non-human primates Peer-reviewed publication highlights early...
View ArticleCapsida Biotherapeutics to Present at Jefferies Cell & Genetic Medicine...
THOUSAND OAKS, Calif., September 20, 2023 — Capsida Biotherapeutics (“Capsida”) today announced that Peter Anastasiou, Chief Executive Officer, will present a corporate update at the following upcoming...
View ArticleCapsida Biotherapeutics Enters Strategic Collaboration With Kate Therapeutics...
Strategic partnership leverages Capsida’s next-generation manufacturing capabilities to enable development of KateTx’s gene therapy medicines for muscle and heart diseases THOUSAND OAKS, Calif. and SAN...
View ArticleCapsida Biotherapeutics to Present at Evercore ISI 2024 Emerging Biotech...
THOUSAND OAKS, Calif., February 21, 2024 — Capsida Biotherapeutics (“Capsida”) today announced that Peter Anastasiou, Chief Executive Officer, will present a corporate update at the Evercore ISI 2024...
View ArticleCapsida Biotherapeutics Announces Promotion of Rob Murphy to Chief...
Promotion reinforces commitment to advancing our wholly owned gene therapy pipeline and strength of in-house manufacturing capabilities THOUSAND OAKS, Calif., March 12, 2024— Capsida Biotherapeutics...
View ArticleCapsida Biotherapeutics to Present New Data on its Wholly Owned Gene Therapy...
Company unveils Parkinson’s disease associated with GBA mutations (PD-GBA) program; two oral presentations feature new data from Capsida’s wholly owned programs in PD-GBA and genetic epilepsy due to...
View ArticleCapsida Biotherapeutics Presents New Preclinical Evidence Indicating Novel...
Dose-dependent rescue of neurological phenotypes, including epileptic seizures, motor deficits, and cognitive impairments, with long-lasting effects in adult mice Capsida poster will also show new data...
View ArticleCapsida Biotherapeutics to Present Preclinical Data for Parkinson’s Disease...
Next-generation gene therapy demonstrates best-in-class potential with majority of neurons transduced in substantia nigra and high levels of GCase supplementation after single IV infusion Broad GCase...
View Article